Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Anika Therapeutics Director Donaldson Resigns.


Business/Technology Editors & Health/Medical Writers

WOBURN, Mass.--(BUSINESS WIRE)--May 9, 2000

Anika Therapeutics, Inc. (Nasdaq: ANIK ANIK Canadian COMSAT ) today announced that Jonathan D. Donaldson has resigned from its board of directors. Donaldson, 50, chairman of Surgical Sealants, Inc., made the decision to leave Anika's board to devote more time to other business and personal commitments, including additional responsibilities as a director of Emerson Hospital Emerson Hospital is a hospital located in Concord, Massachusetts, founded in 1911 on forty acres donated by Charles Emerson. As of 2006, it is a full-service, non-profit community hospital and acute care medical center with 177 beds, providing advanced medical services to over  in Concord, Massachusetts.

J. Melville Engle, chairman, president and chief executive officer, said the company is initiating a search to find a replacement for Donaldson's position on the board. "Jona has been one of the key contributors to Anika's development since its inception. His insights and guidance will be missed. We wish him all the best in his other activities," Engle said.

Anika Therapeutics, Inc. (www.anikatherpeutics.com) develops, manufactures and commercializes therapeutic products and devices intended to promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid hyaluronic acid: see mucopolysaccharide.
Hyaluronic acid

A polysaccharide which is an integral part of the gel-like substance of animal connective tissue; it supposedly serves as a lubricant and shock absorbent in the joints.
 (HA), a naturally occurring, biocompatible biocompatible /bio·com·pat·i·ble/ (-kom-pat´i-b'l) being harmonious with life; not having toxic or injurious effects on biological function.  polymer found throughout the body. In addition to ORTHOVISC(R), a treatment of osteoarthritis osteoarthritis
 or osteoarthrosis or degenerative joint disease

Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first.
 of the knee (not approved for sale in the U.S.), Anika markets HYVISC(R) in the U.S. for the treatment of equine osteoarthritis through Boehringer Ingelheim Vetmedica, Inc. and manufactures AMVISC(R) and AMVISC(R) Plus, HA viscoelastic Adj. 1. viscoelastic - having viscous as well as elastic properties
natural philosophy, physics - the science of matter and energy and their interactions; "his favorite subject was physics"
 products for ophthalmic surgery, for Bausch & Lomb Surgical.
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:May 9, 2000
Words:228
Previous Article:ADVISORY/SAGA Canada presents the 'Enabling the E-conomy: E-Business Integration Simplified' Executive Briefing.
Next Article:CSP CEO to Interview On RadioWallStreet.com From Aea Micro Cap Conference.
Topics:



Related Articles
Anika Therapeutics Diluted Loss Per Share for 1999 is $0.24 Versus $0.26 as Previously Reported.
Anika Therapeutics Promotes Sherwood to VP, Research and Development.
Update for Anika Therapeutics, Inc. Shareholders By The Desmond Law Firm.
Shareholders Have Sued Anicom, Anika and Vari-L for Securities Fraud, Says Berman, DeValerio & Pease LLP.
Anika Therapeutics Enters Into New Supply Agreement With Bausch & Lomb.
Anika Therapeutics Reaches Agreement to Settle Securities Class Action Suit.
Douglas R. Potter Named Chief Executive Officer of Anika Therapeutics Inc.; Charles H. Sherwood Named President and Chief Operating Officer.
ANIKA INITIATES INCERT-S ANTI-ADHESION THERAPY CLINICAL TRIAL.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles